Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A comparative study of the effect of the Time for Dementia programme on medical students.
Banerjee S, Jones C, Wright J, Grosvenor W, Hebditch M, Hughes L, Feeney Y, Farina N, Mackrell S, Nilforooshan R, Fox C, Bremner S, Daley S. Banerjee S, et al. Among authors: nilforooshan r. Int J Geriatr Psychiatry. 2021 Jul;36(7):1011-1019. doi: 10.1002/gps.5532. Epub 2021 Mar 28. Int J Geriatr Psychiatry. 2021. PMID: 33686788 Free PMC article.
How do we enhance undergraduate healthcare education in dementia? A review of the role of innovative approaches and development of the Time for Dementia Programme.
Banerjee S, Farina N, Daley S, Grosvenor W, Hughes L, Hebditch M, Mackrell S, Nilforooshan R, Wyatt C, de Vries K, Haq I, Wright J. Banerjee S, et al. Among authors: nilforooshan r. Int J Geriatr Psychiatry. 2017 Jan;32(1):68-75. doi: 10.1002/gps.4602. Epub 2016 Oct 10. Int J Geriatr Psychiatry. 2017. PMID: 27723124 Free PMC article. Review.
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu AV, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Gray R; ATLAS Trialists Group. Howard R, et al. Among authors: nilforooshan r. Lancet Psychiatry. 2018 Jul;5(7):553-563. doi: 10.1016/S2215-0366(18)30141-X. Epub 2018 Jun 4. Lancet Psychiatry. 2018. PMID: 29880238 Free PMC article. Clinical Trial.
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.
Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R; Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group. Howard R, et al. Among authors: nilforooshan r. JAMA Neurol. 2020 Feb 1;77(2):164-174. doi: 10.1001/jamaneurol.2019.3762. JAMA Neurol. 2020. PMID: 31738372 Free PMC article. Clinical Trial.
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT.
Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, Pank L, O’Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Wilcock G, Nilforooshan R. Howard R, et al. Among authors: nilforooshan r. Southampton (UK): NIHR Journals Library; 2020 Apr. Southampton (UK): NIHR Journals Library; 2020 Apr. PMID: 32338849 Free Books & Documents. Review.
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Banerjee S, High J, Stirling S, Shepstone L, Swart AM, Telling T, Henderson C, Ballard C, Bentham P, Burns A, Farina N, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Tabet N. Banerjee S, et al. Among authors: nilforooshan r. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. Lancet. 2021. PMID: 34688369 Free PMC article. Clinical Trial.
Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial.
Henderson C, Knapp M, Stirling S, Shepstone L, High J, Ballard C, Bentham P, Burns A, Farina N, Fox C, Fountain J, Francis P, Howard R, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien JT, Price A, Swart AM, Tabet N, Telling T, Thomas AJ, Banerjee S. Henderson C, et al. Among authors: nilforooshan r. Int Psychogeriatr. 2022 Oct;34(10):905-917. doi: 10.1017/S1041610222000436. Epub 2022 Jul 19. Int Psychogeriatr. 2022. PMID: 35852256 Free article. Clinical Trial.
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Swart AM, Telling T, Tabet N. Banerjee S, et al. Among authors: nilforooshan r. Health Technol Assess. 2023 Oct;27(23):1-108. doi: 10.3310/VPDT7105. Health Technol Assess. 2023. PMID: 37929672 Free PMC article. Clinical Trial.
Health management and pattern analysis of daily living activities of people with dementia using in-home sensors and machine learning techniques.
Enshaeifar S, Zoha A, Markides A, Skillman S, Acton ST, Elsaleh T, Hassanpour M, Ahrabian A, Kenny M, Klein S, Rostill H, Nilforooshan R, Barnaghi P. Enshaeifar S, et al. Among authors: nilforooshan r. PLoS One. 2018 May 3;13(5):e0195605. doi: 10.1371/journal.pone.0195605. eCollection 2018. PLoS One. 2018. PMID: 29723236 Free PMC article.
54 results